Zirconium phosphate disinfection recharging and conditioning

Information

  • Patent Grant
  • 11883794
  • Patent Number
    11,883,794
  • Date Filed
    Thursday, February 25, 2021
    3 years ago
  • Date Issued
    Tuesday, January 30, 2024
    3 months ago
Abstract
The invention relates to systems and methods for disinfecting, recharging, and conditioning zirconium phosphate in a reusable sorbent module. The systems and methods provide for reuse of a zirconium phosphate sorbent module after dialysis.
Description
FIELD OF THE INVENTION

The invention relates to systems and methods for disinfecting, recharging, and conditioning zirconium phosphate in a reusable sorbent module. The systems and methods provide for reuse of a zirconium phosphate sorbent module after dialysis.


BACKGROUND

Zirconium phosphate containing sorbent cartridges are used in dialysis to remove ammonium, potassium, calcium, and magnesium ions from dialysate, allowing the dialysate to be reused. Known systems require zirconium phosphate to be removed from a sorbent cartridge, transported to a reprocessor, treated, and placed into a new sorbent cartridge, increasing costs and waste associated with reuse of zirconium phosphate. Known systems and methods also cannot reuse a zirconium phosphate sorbent module by concurrently disinfecting the zirconium phosphate to reduce the microbial load to acceptable levels, recovering the capacity of the zirconium phosphate, and conditioning the zirconium phosphate to an appropriate chemical state for dialysis. Hence, there is a need for systems and methods that can quickly and effectively disinfect, recharge and condition zirconium phosphate in a reusable sorbent module. There is further a need for systems and methods optimized to carry out all three steps with the least amount of waste at reduced cost than known systems and methods.


SUMMARY OF THE INVENTION

The first aspect of the invention relates to a method of recharging zirconium phosphate in a zirconium phosphate sorbent module. In any embodiment, the method can include flowing a disinfectant solution through the zirconium phosphate sorbent module; and flowing a brine solution through the zirconium phosphate sorbent module.


In any embodiment, the method can include the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.


In any embodiment, the disinfectant solution can be a peracetic acid solution and the brine solution can contain acetic acid, sodium acetate, and sodium chloride.


In any embodiment, the brine solution can contain between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.


In any embodiment, the disinfection solution can contain between 0.1 to 3 wt % peracetic acid.


In any embodiment, the disinfection solution can contain between 0.1 to 3 wt % peracetic acid and between 0.1 to 15 wt % acetic acid.


In any embodiment, the step of flowing the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.


In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature while flowing the mixture through the zirconium phosphate sorbent module.


In any embodiment, the mixture of disinfectant solution and brine solution can be maintained at room temperature for a set period of time, and then heated for a set period of time.


In any embodiment, the mixture of disinfectant solution and brine solution can have between 0.1 and 3.0 wt % peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.


In any embodiment, the step of flowing a disinfectant solution through the zirconium phosphate sorbent module can include flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.


In any embodiment, the step of flowing a brine solution through the zirconium phosphate sorbent module can include flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.


In any embodiment, the brine solution can be flowed through the zirconium phosphate sorbent module after the peracetic acid is flowed through the zirconium phosphate sorbent module.


In any embodiment, the peracetic acid solution can be flowed through the zirconium phosphate sorbent module after the brine solution is flowed through the zirconium phosphate sorbent module.


In any embodiment, the method can include the step of heating the brine solution prior to flowing the brine solution through the zirconium phosphate sorbent module.


In any embodiment, the brine solution can be heated to a temperature up to 100° C.


In any embodiment, the method can include flowing the brine solution to a static mixer and flowing the disinfectant solution to the static mixer prior to flowing the mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.


In any embodiment, the step of flowing a mixture of the disinfectant solution and the brine solution through the zirconium phosphate sorbent module can include flowing the mixture from a combined disinfectant solution and brine solution source.


In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.


In any embodiment, the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module can include flowing between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L of water through the zirconium phosphate sorbent module.


In any embodiment, the method can include holding the disinfectant solution in the zirconium phosphate sorbent module.


In any embodiment, the disinfectant solution can be held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.


In any embodiment, the method can include flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.


In any embodiment, the method can include intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.


In any embodiment, the method can include rinsing the zirconium phosphate sorbent module with water after flowing the disinfectant solution through the zirconium phosphate sorbent module and prior to flowing the brine solution through the zirconium phosphate sorbent module.


In any embodiment, the brine solution, the water, and the disinfectant solution can be flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.


The features disclosed as being part of the first aspect of the invention can be in the first aspect of the invention, either alone or in combination.


The second aspect of the invention is drawn to a zirconium phosphate recharging flow path. In any embodiment, the zirconium phosphate recharging flow path can include (i) a water source and a combined disinfectant solution and brine solution source; (ii) a zirconium phosphate sorbent module inlet and a zirconium phosphate sorbent module outlet; wherein the zirconium phosphate sorbent module inlet and the zirconium phosphate sorbent module outlet are fluidly connectable to a zirconium phosphate sorbent module; (iii) at least one pump for flowing fluid from the water source and the combined disinfectant solution and brine solution source to the zirconium phosphate sorbent module inlet; and; (iv) a zirconium phosphate effluent line fluidly connectable to the zirconium phosphate sorbent module outlet.


In any embodiment, the combined disinfectant solution and brine solution source can contain between 0.1 and 3.0 wt % peracetic acid, between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.


In any embodiment, the zirconium phosphate recharging flow path can include a second pump.


In any embodiment, the zirconium phosphate recharging flow path can include a static mixer, the static mixer fluidly connected to the water source and the combined disinfectant solution and brine solution source.


The features disclosed as being part of the second aspect of the invention can be in the second aspect of the invention, either alone or in combination.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a flow chart of a method for disinfecting, recharging and conditioning zirconium phosphate.



FIG. 2 is a flow chart of a method for disinfecting, recharging and conditioning zirconium phosphate with a combined disinfection and recharging solution.



FIG. 3 is a flow path for disinfection, recharging and conditioning of zirconium phosphate in a reusable sorbent module.



FIG. 4 is a flow path for disinfection, recharging and conditioning of zirconium phosphate using a combined disinfection and recharging solution.





DETAILED DESCRIPTION OF THE INVENTION

Unless defined otherwise, all technical and scientific terms used generally have the same meaning as commonly understood by one of ordinary skill in the art.


The articles “a” and “an” are used to refer to one or to over one (i.e., to at least one) of the grammatical object of the article. For example, “an element” means one element or over one element.


The term “acetic acid” refers to CH3CO2H in an aqueous solution.


A “brine solution” is a solution containing sodium chloride, an acid, and the sodium salt of the acid.


The term “combined disinfectant solution and brine solution source” refers to any source of a fluid containing both a disinfectant and a brine solution.


The term “comprising” includes, but is not limited to, whatever follows the word “comprising.” Use of the term indicates the listed elements are required or mandatory but that other elements are optional and may be present.


A “concentrated” solution refers to a solution having at least one solute in a higher concentration than intended for use.


The term “consisting of” includes and is limited to whatever follows the phrase “consisting of.” The phrase indicates the limited elements are required or mandatory and that no other elements may be present.


The term “consisting essentially of” includes whatever follows the term “consisting essentially of” and additional elements, structures, acts or features that do not affect the basic operation of the apparatus, structure or method described.


A “dilute” solution refers to a concentrated solution after addition of a solvent to lower the solute concentration.


The term “direction opposite to a flow direction during therapy” refers to a direction of fluid flow through a component that is in reserver to an initial flow direction, or 180° to the initial direction of fluid flow, through the component during dialysis therapy.


The term “disinfectant solution” refers to any solution capable of destroying or removing bacterial contaminants from a reusable sorbent module.


The terms “flowing” or to “flow” refer to the movement of a fluid, gas, or mixtures thereof.


The term “flow rate” refers to a volume of fluid moved in a flow path in a given period of time.


A “fluid” is a liquid substance optionally having a combination of gas and liquid phases in the fluid. Notably, a liquid, as used herein, can therefore also have a mixture of gas and liquid phases of matter.


The term “fluidly connectable,” “fluidly connect,” “for fluid connection,” and the like, refer to the ability of providing for the passage of fluid, gas, or a combination thereof, from one point to another point. The two points can be within or between any one or more of compartments, modules, systems, components, and rechargers, all of any type. The connection can optionally be disconnected and then reconnected.


The term “generate” refers to creating a fluid with a specified concentration, pH, temperature, and/or volume from one or more fluid sources.


The term “heating” or to “heat” refers to raising the temperature of a material.


The term “holding a disinfectant solution” or to “hold a disinfectant solution” refers to adding a disinfectant solution to a component without immediate removal of the disinfectant solution. The term “holding a disinfectant solution” can also refer to flowing a disinfectant solution through the component at a low flow rate or an intermittent flow rate.


The term “intermittently” refers to a process that starts and stops multiple times.


The term “maintained at room temperature” or to “maintain at room temperature” refers to keeping a substance from increasing or decreasing in temperature substantially from room temperature.


The term “mixture” refers to a fluid having at least two components, the two components combined to form a substantially homogeneous substance.


The term “peracetic acid” refers to CH3CO3H in an aqueous solution.


The term “peracetic acid solution” refers to a solution of peracetic acid, acetic acid and hydrogen peroxide


The term “pump” refers to any device that causes the movement of fluids, gases, or combinations thereof, by applying suction or pressure.


“Recharging” refers to treating a sorbent material to restore the functional capacity of the sorbent material to put the sorbent material back into a condition for reuse or use in a new dialysis session. In some instances, the total mass, weight and/or amount of “rechargeable” sorbent materials remain the same. In some instances, the total mass, weight and/or amount of “rechargeable” sorbent materials change. Without being limited to any one theory of invention, the recharging process may involve exchanging ions bound to the sorbent material with different ions, which in some instances may increase or decrease the total mass of the system. However, the total amount of the sorbent material will in some instances be unchanged by the recharging process. Upon a sorbent material undergoing “recharging,” the sorbent material can then be said to be “recharged.”


The term “rinsing” or to “rinse” refers to flowing water through a component to remove substances from the component.


The term “room temperature” refers to the ambient temperature in an environment without additional heating or cooling. In general, room temperature can be considered between 15 and 30° C.


The term “set period of time” refers to a specific amount of time elapsed between two events.


The term “sodium acetate” refers to CH3CO2Na in an aqueous solution.


The term “sodium chloride” refers to NaCl.


A “sorbent cartridge module” or “sorbent module” means a discreet component of a sorbent cartridge. Multiple sorbent cartridge modules can be fitted together to form a sorbent cartridge of two, three, or more sorbent cartridge modules. In some embodiments, a single sorbent cartridge module can contain all of the necessary materials for dialysis. In such cases, the sorbent cartridge module can be a “sorbent cartridge.”


A “static mixer” is a component configured to receive fluids from one or multiple sources and to mix the fluids together. The static mixer may include components that agitate the fluids to further mixing.


The term “void volume” refers to a volume contained in a cartridge, not including a sorbent or any other material, through which liquid can flow. The term “void volume” can also refer to the volume of a cartridge or container available for a liquid or gas to fill the cartridge or container.


The term “water,” as used herein, refers to H2O in a liquid state. “Water” can refer to portable water, drinking water, purified water, deionized water, tap water, or a solution containing one or more solutes dissolved in the water. The water shall not be limited to any specific purity, disinfection time, toxicity, microbial load, or any other indicator of water quality.


A “water source” is a fluid source from which water can be obtained.


“Zirconium phosphate” is a sorbent material that removes cations from a fluid, exchanging the removed cations for different cations.


A “zirconium phosphate effluent line” is a fluid passageway, tube, or path of any kind into which fluid exiting a zirconium phosphate sorbent module will flow.


A “zirconium phosphate module” or “zirconium phosphate sorbent module” is a sorbent module containing zirconium phosphate.


A “zirconium phosphate sorbent module inlet” is a connector through which a fluid, slurry, or aqueous solution can enter a zirconium phosphate sorbent module.


A “zirconium phosphate sorbent module outlet” is a connector through which a fluid, slurry, or aqueous solution can exit a zirconium phosphate sorbent module.


A “zirconium phosphate recharging flow path” is a path through which fluid can travel while recharging zirconium phosphate in a reusable zirconium phosphate sorbent module.


Zirconium Phosphate Recharging, Disinfection, and Conditioning



FIG. 1 is a flow chart illustrating a method for disinfecting, recharging, and conditioning zirconium phosphate. To reuse zirconium phosphate in dialysis, the method must achieve three steps. The cartridge must be disinfected to reduce the microbial load to acceptable levels, illustrated as disinfection steps 103-105; the capacity of the zirconium phosphate must be recovered, illustrated as recharging step 106; and the zirconium phosphate must be returned to an appropriate chemical state, or conditioned, which occurs during step 106-107.


The method of disinfecting the zirconium phosphate in a zirconium phosphate sorbent module can begin in step 101. During use in dialysis potassium, calcium, magnesium, and ammonium ions are adsorbed by the zirconium phosphate. In step 102, the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy. The spent dialysate can have proteinaceous and other compounds that interact with the disinfectant used in subsequent steps. Rinsing the zirconium phosphate sorbent module with water removes the proteinaceous compounds. Any volume of water sufficient to remove the spent dialysate can be flowed through the zirconium phosphate sorbent module in step 102, including between 0.5 and 4.0 L, between 0.5 and 1.5 L, between 1.0 and 3.0 L, between 1.5 and 3.0 L, or between 2.0 and 4.0 L. In a preferred embodiment, about 1.0 L of water is flowed through the zirconium phosphate sorbent module in rinsing step 102. The rinse water can be flowed through the zirconium phosphate sorbent module at any temperature. In certain embodiments, the rinse water can be heated to aid in removal of spent dialysate or for pre-heating the zirconium phosphate sorbent module. Pre-heating the zirconium phosphate sorbent module can increase efficiency where the zirconium phosphate sorbent module may have been stored at low temperatures, such as 10° C. or less. The rinse water can be heated to any temperature between 20 and 100° C.


After rinsing the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be filled with a disinfectant solution in step 103. An aqueous peracetic acid solution can be the disinfectant solution. The peracetic acid solution can have any concentration of peracetic acid sufficient to disinfect the zirconium phosphate sorbent module, including between 0.1 and 5 wt %. In a preferred embodiment, the peracetic acid solution is 1 wt % in water. The volume of peracetic acid flowed into the zirconium phosphate sorbent module can be enough to fill the zirconium phosphate sorbent module, and can be between 100% to 200% or more of the void volume of the zirconium phosphate sorbent module. In a preferred embodiment, a volume of peracetic acid solution flowed into the zirconium phosphate sorbent module is 150% of the module void volume. With a 1.2 L zirconium phosphate sorbent module, 1.8 L of peracetic acid solution can be flowed into the module in step 103.


The peracetic acid solutions can be mixtures of peracetic acid, acetic acid and hydrogen peroxide. Typically, peracetic acid is the result of mixing acetic acid and hydrogen peroxide together, resulting in the generation of peracetic acid in equilibrium with the acetic acid and hydrogen peroxide. There are several varieties of peracetic acid solution available, which vary in the concentration of peracetic acid, acetic acid, and hydrogen peroxide. In addition to peracetic acid, the disinfectant solution can be a combined peracetic acid and acetic acid solution, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The combined disinfectant and acid solution can contain between 0.1 and 3 wt % peracetic acid and 0.1 to 15 wt % acetic acid. Alternatively, hydrogen peroxide can be added to the peracetic acid, which increases the effectiveness of the disinfection as compared to peracetic acid alone. The addition of hydrogen peroxide can drive the equilibrium of peracetic acid, hydrogen peroxide, and acetic acid towards generation of peracetic acid as the initial peracetic acid is consumed. Further, both peracetic acid and hydrogen peroxide can be used as disinfectants alone. Both peracetic acid and hydrogen peroxide operate by oxidation, with each having an oxidation potential of 1.8 electron volts. Adding hydrogen peroxide to the peracetic acid solution can increase the total oxidation potential of the mixture, resulting in a more potent disinfectant. Chemical formulations including mixtures of peracetic acid and hydrogen peroxide are known. The mixtures can be clear, colorless liquids that are miscible with water. The mixtures can be oxidizing agents and disinfectants with a pungent odor, having peracetic acid, acetic acid, and hydrogen peroxide in equilibrium. Thermal decomposition of the mixtures occurs at temperatures above 60° C. Known compositions of peracetic acid and hydrogen peroxide solutions are available from Evonik, a German corporation. Examples of peracetic acid and hydrogen peroxide solutions include PERACLEAN® 5 having 5% peracetic acid and 26% hydrogen peroxide, PERACLEAN® 10 having 10% peracetic acid and 20% hydrogen peroxide, PERACLEAN® 15 having 15% peracetic acid and 21% hydrogen peroxide, PERACLEAN® 35 having 35% peracetic acid and 7% hydrogen peroxide, and PERACLEAN® 40 having 39% peracetic acid and 4% hydrogen peroxide. As the concentration of peracetic acid in the mixture is decreased, additional hydrogen peroxide can be added to increase effectiveness of the mixture. The formulations, or any other source of peracetic acid and hydrogen peroxide can be diluted to obtain a solution with desired concentrations of peracetic acid and hydrogen peroxide.


In step 104, the disinfectant solution can be held in the zirconium phosphate sorbent module for a sufficient length of time to ensure complete disinfection of the zirconium phosphate sorbent module. The hold time can be any length of time, including between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes. The length of the hold time can depend on the temperature of the zirconium phosphate sorbent module, and in a preferred embodiment the hold time can be 15 minutes at 22° C. Alternatively, the disinfectant solution can be heated in steps 103-104 to a temperature higher than 22° C., which increases the efficiency of disinfection. The disinfectant can be heated to any temperature, including between 22° C. and 100° C., between 22° C. and 50° C., between 22° C. and 35C, between 30° C. and 50° C., between 35° C. and 65° C., between 50° C. and 75° C., or between 60° C. and 100° C. During step 104, a low flow rate of fluid through the zirconium phosphate sorbent module can be used to prevent pressure build up in the cartridge resulting from the degradation of peracetic acid. The low flow rate can vary from 1 to 20 ml/min. the low flow rate can have an on/off flow profile by intermittently switching the flow rate on and off while holding the disinfectant solution. The flow rate during the disinfectant hold can be set as 55 ml/min for 15 seconds and 0 ml/min for 45 seconds. In a preferred embodiment, the hold flow rate is 15 cycles of 55 ml/min for 15 seconds and 0-ml/min for 45 seconds.


In step 105, the zirconium phosphate module can be rinsed with water, allowing a buffer of water to be present between the peracetic acid solution and the subsequent brine solution. Step 105 is optional, and the method can proceed without rinsing between the peracetic acid step 104 and the brine step 106. When rinsing with water between steps 104 and 106, the volume of water used can vary between 0 and 1.0 L or more. In a preferred embodiment, step 105 is omitted. However, the zirconium phosphate module can be rinsed if material degradation to the cartridge housing or other components is detected. Material degradation may be an issue if the disinfectant used is a heated mixture of peracetic acid and acetic acid, or a mixture of peracetic acid and brine at temperatures around 80° C.


In step 106 a brine solution can be flowed through the zirconium phosphate sorbent module to recharge the zirconium phosphate. The brine solution can include an aqueous solution of sodium chloride, and acid, and the sodium salt of the acid. The brine solution provides additional disinfection of the zirconium phosphate; recovers the capacity of the zirconium phosphate by removing ammonium, potassium, calcium, and magnesium ions in exchange for sodium and hydrogen ions; and leaves the zirconium phosphate at the desired pH, or in the proper/desired sodium to hydrogen ion ratio for dialysis. Although FIG. 1 illustrates flowing the brine solution through the zirconium phosphate sorbent module in step 106 after flowing the disinfectant solution through the zirconium phosphate sorbent module in step 104, the order can be reversed, with the brine solution flowed through the zirconium phosphate module first, followed by the disinfectant solution. Flowing the disinfectant solution through the zirconium phosphate sorbent module after the brine solution can reduce the risk of the brine solution contaminating the cartridge. Further, the disinfectant solution can be kept in the zirconium phosphate sorbent module during storage, preventing microbial growth in the zirconium phosphate sorbent module during storage.


Any acid, sodium salt of an acid, and sodium salt can be used in the brine solution. In a preferred embodiment, the brine solution includes sodium chloride, acetic acid, and sodium acetate. However, the brine solution can be a glycolic/glycolate solution, a citric acid/citrate solution, a propionate/propionic acid solution, monobasic phosphate, or any combination thereof. The relative ratios of the acid and sodium salt of the acid in the brine solution can be varied depending on the desired zirconium phosphate pH. With a sodium acetate/acetic acid brine solution, the concentration of sodium chloride can vary between 0 and 5.0 M, the concentration of acetic acid can vary between 0.1 and 2.0 M, and the concentration of sodium acetate can vary between 0.1 and 2 M, where the upper concentration limits are only limited by solubility. The sodium chloride can be omitted in certain embodiments, and the zirconium phosphate sorbent module can be recharged with an acid and the sodium salt of the acid. The sodium salt of the acid can provide sodium ions and the acid can provide the hydrogen ions for recharging. The upper limit of the sodium salt and acid concentration is based on the solubility of the sodium salt and acid, and can depend on the type of sodium salt used and the acid concentration used. In a preferred embodiment, the brine solution contains about 4.854 M sodium chloride, 0.350 M sodium acetate, and 0.350 M acetic acid. Table 1 provides non-limiting examples of brine solutions and the resulting initial therapy zirconium phosphate effluent pH. In each case, the solution was heated to 80° C. prior to use. As shown in Table 1, a higher ratio of sodium acetate to acetic acid results in a higher solution pH, and therefore a higher initial therapy zirconium phosphate effluent pH. The relative amounts of acid, base, and sodium salt can be set to generate a brine solution resulting in a desired initial effluent pH.















TABLE 1






Total Na
NaCl
NaAce
HAce

Initial


Solution
(M)
(M)
(M)
(M)
pH
Effluent PH





















1
4.00
4.00
0.00
0.20
2.75
4.40


2
4.00
3.98
0.02
0.20
3.74
5.42


3
4.00
3.88
0.12
0.40
4.23
5.99


4
4.00
3.60
0.40
0.40
4.75
6.58









Each of the solutions in Table 1 are combinations of sodium chloride, sodium acetate, and acetic acid. One of skill in the art will understand that other combinations can be used in place of sodium acetate and acetic acid, including sodium diacetate. The sodium diacetate can be mixed with sodium acetate or acetic acid to result in a brine solution having a desired pH. Sodium diacetate and sodium acetate are solids, which may be easier to ship and store. The sodium diacetate and/or sodium acetate can be shipped and stored as a dry powder, eliminating the need to ship and handle acetic acid.


During step 106, the brine solution can optionally be heated. Heating the brine solution increases the efficiency of the recharging process. The brine solution can be heated to any temperature between 22 and 100° C., including between 22 and 40° C., between 22 and 60° C., between 35 and 50° C., between 45 and 70° C., between 55 and 85° C., between 60 and 90° C., between 75 and 85° C., or between 70 and 100° C. In a preferred embodiment, the brine solution is heated to about 80° C. during step 106. The brine solution can be used at lower temperatures with a decrease in efficiency.


The volume of brine solution to recharge the zirconium phosphate depends on the cations bound to the zirconium phosphate during therapy, and the size of the zirconium phosphate sorbent module, the temperature of the brine solution, and the concentrations of sodium chloride, acid, and sodium salt of the acid used in the brine solution. In a preferred embodiment, the volume of brine is 6.2 L for a zirconium phosphate sorbent module containing 2.69 kg of ZP with a capacity of 1 mEq cation per gram of ZP.


After flowing the brine solution through the zirconium phosphate sorbent module, the zirconium phosphate sorbent module can be rinsed in step 107 by flowing water through the zirconium phosphate sorbent module. The rinsing is necessary to remove the brine solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session. The rinse water volume can vary from 100% to 500% of the cartridge void volume. In a preferred embodiment, the volume of rinse water is about 333% of the cartridge void volume, or 4 L for a zirconium phosphate sorbent module with a 1.2 L void volume. About 99% of the brine solution can be removed from the zirconium phosphate sorbent module during step 107, which leaves the zirconium phosphate sorbent module with an average concentration remaining of 52 mM total sodium, which is appropriate for storage and use during the next therapy session. The rinsing step 107 can occur during recharging of the zirconium phosphate sorbent module, or the zirconium phosphate sorbent module can be rinsed in the dialysis system just prior to use. Rinsing the zirconium phosphate sorbent module just prior to use allows the disinfectant solution, if the disinfectant step is performed after the brine step, to remain in the zirconium phosphate sorbent module during storage, reducing microbial growth. The method can end in step 108, with a zirconium phosphate sorbent module in condition for reuse in dialysis. Alternatively, the zirconium phosphate module can be fully or partially drained after recharging and conditioning for storage, which decreases the weight and exposure to water during storage.


The direction of flow of brine through the zirconium phosphate sorbent module during step 106 can be in a direction opposite to a flow direction during therapy. During therapy, spent dialysate enters the bottom of the module, flows upwards against gravity, and exits the top of the cartridge. During recharging the brine can enter the zirconium phosphate sorbent module at the top and exit through the bottom, flowing with gravity. Alternatively, the spent dialysate flow direction during therapy can be downward, and the brine can flow upwardly through the zirconium phosphate sorbent module during recharging. The rinse and disinfection flow direction during steps 102-105 and 107 can be either the same or opposite to the flow direction during therapy. Alternatively, the direction of flow of brine during recharging can be the same as the flow direction during therapy, however, flowing brine through the zirconium phosphate module in the same direction as flow during therapy may require additional brine volume for recharging. In a preferred embodiment, the rinse and disinfection flow direction is the same direction as the brine flow direction.



FIG. 2 illustrates an alternative embodiment of the disinfection, recharging, and conditioning of zirconium phosphate. The method can start in step 201. In step 202, the zirconium phosphate sorbent module can be rinsed with water by flowing water through the zirconium phosphate sorbent module to remove any spent dialysate left in the module after therapy. In step 203 a mixture of disinfectant solution and brine can be flowed through the zirconium phosphate sorbent module. The disinfectant solution can be added to the brine, and the process for recharging, disinfecting, and conditioning the zirconium phosphate sorbent module can be similar to the process illustrated in FIG. 1, allowing disinfection, capacity recovery, and conditioning in one step. The mixture of disinfectant solution and brine disinfects and recharges the zirconium phosphate in a single step, as opposed to separate steps as illustrated in FIG. 1. The concentrations of peracetic acid, sodium chloride, sodium acetate, and acetic acid in the mixture can be the same as the individual solutions shown in FIG. 1. The mixture of brine and peracetic acid may help stabilize the peracetic acid in the disinfectant solution because the presence of the acetate buffer keeps the peracetic acid/acetic acid equilibrium shifted to the peracetic acid side. During step 203, the mixture of peracetic acid and brine can be held in the zirconium phosphate sorbent module for any length of time sufficient to ensure complete disinfection or alternatively, the mixture of peracetic acid and brine can be continuously flowed through the zirconium phosphate sorbent module. In a preferred embodiment, the mixture of peracetic acid and brine is heated to about 80° C. in step 203, however the solutions may alternatively be at a lower, unheated temperature, such as room temperature. The mixture of peracetic acid and brine can be heated to any temperature between 22 and 100° C., including between 22 and 40° C., between 22 and 60° C., between 35 and 50° C., between 45 and 70° C., between 55 and 85° C., between 60 and 90° C., between 75 and 85° C., or between 80 and 100° C. Alternatively, the mixture of peracetic acid and brine can be kept at room temperature for a set period of time to ensure complete disinfection, and then heated for a set period of time to increase the efficiency of the recharging process. The mixture of peracetic acid and brine solution can be maintained at room temperature for 5-30 minutes, and then subsequently heated. In a preferred embodiment, about 6.2 L of a solution of 1 wt % peracetic acid and the brine solutions described can be flowed through the zirconium phosphate sorbent module at about 80° C. In step 204, the zirconium phosphate sorbent module can be rinsed by flowing water through the zirconium phosphate sorbent module to remove the brine and peracetic acid solution in the zirconium phosphate sorbent module to appropriate levels for storage and use during the next therapy session. The method can end in step 205 with a zirconium phosphate sorbent module in condition for reuse in dialysis.



FIG. 3 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconium phosphate sorbent module 302. A zirconium phosphate sorbent module 302 can connect to the zirconium phosphate recharging flow path 301 through zirconium phosphate sorbent module inlet 303 and zirconium phosphate sorbent module outlet 304. A zirconium phosphate effluent line 311 can be fluidly connected to the zirconium phosphate sorbent module outlet 304 for removal of solutions after the solutions pass through the zirconium phosphate sorbent module 302. Pump 307 provides a driving force for flowing fluids through the zirconium phosphate recharging flow path 301. A brine source 305, containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid is fluidly connected to the zirconium phosphate recharging flow path 301. Disinfectant source 306 can contain a disinfectant solution, such as peracetic acid. Water source 310 is also fluidly connected to the zirconium phosphate recharging flow path 301. The water source 310 can contain any water as defined herein, including deionized water. The water can be obtained from a tap such as a faucet or from any other readily available source in a home setting. Water obtained from a tap is not limited to any specific country requirements and contemplates various water specifications insofar as various countries may have different requirements. In general, the water should not be contained by infectious agents, toxic chemicals, or radiological hazards. The water can comport with WHO requirements for potable or drinking water. However, the invention contemplating water from many sources having various purity and quality levels and requirements, shall not be limited in such respects. Valve 308 controls the movement of fluid through the zirconium phosphate recharging flow path 301 and zirconium phosphate sorbent module 302. A static mixer 309 can optionally be included to ensure complete mixing of solutions prior to entering the zirconium phosphate sorbent module 302. For example, when a mixture of brine and peracetic acid is used for single step disinfecting and recharging, the static mixer 309 ensures that the peracetic acid and brine are mixed to generate a dilute mixture of brine and peracetic acid for simultaneous recharging and disinfection. One of skill in the art will understand that different pump and valve arrangements can be used with the system illustrated in FIG. 3. The brine source 305, disinfectant source 306, and water source 310 can be connected to the zirconium phosphate recharging flow path 301 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphate recharging flow path 301.


The zirconium phosphate recharging flow path 301 can flow solutions through the zirconium phosphate sorbent module 302 in a sequential order or simultaneously. As illustrated in FIG. 1, the zirconium phosphate recharging flow path 301 can flow water, disinfectant, brine, and water again through the zirconium phosphate sorbent module 302 sequentially. The zirconium phosphate recharging flow path 301 can flow water through the zirconium phosphate sorbent module 302, followed by simultaneously flowing peracetic acid and brine through the zirconium phosphate sorbent module 302 as illustrated in FIG. 2.


The solutions in the brine source 305 and disinfectant source 306 can be any concentration, including the concentrations shown in FIGS. 1-2. The solutions in brine source 305 and/or disinfectant source 306 can be concentrated solutions. The brine solution can have sodium chloride, acid, and sodium salt of the acid at concentrations higher than that to be used in recharging the zirconium phosphate sorbent module 302. The brine solution and water can be simultaneously flowed to static mixer 309 to dilute the concentrated brine solution in the recharging steps generating a dilute brine solution usable for recharging the zirconium phosphate. Similarly, a concentrated disinfectant solution and water can be simultaneously flowed to static mixer 309 to dilute the disinfectant solution during the disinfecting steps, generating a dilute disinfectant solution for disinfecting the zirconium phosphate. A heater and/or heat exchanger (not shown) can be included for heating the brine solution, the disinfectant solution, and/or the rinse water prior to flowing the solutions through the zirconium phosphate sorbent module 302.



FIG. 4 illustrates a non-limiting embodiment of a flow path for disinfecting, recharging, and conditioning of a zirconium phosphate sorbent module 402 with a combined brine and disinfectant fluid, as illustrated in FIG. 2. A zirconium phosphate sorbent module 402 can connect to the zirconium phosphate recharging flow path 401 through zirconium phosphate sorbent module inlet 403 and zirconium phosphate sorbent module outlet 404. A zirconium phosphate effluent line 410 can be fluidly connected to the zirconium phosphate sorbent module outlet 404 for removal of solutions after the solutions pass through the zirconium phosphate sorbent module 402. Pump 407 provides a driving force for flowing fluids through the zirconium phosphate recharging flow path 401. A combined disinfectant solution and brine solution source 405, containing a sodium salt and buffer, such as sodium chloride, sodium acetate, and acetic acid, and a disinfectant such as peracetic acid, can be fluidly connected to the zirconium phosphate recharging flow path 401. Water source 406 is also fluidly connected to the zirconium phosphate recharging flow path 401. Valve 408 controls the movement of fluid through the zirconium phosphate recharging flow path 401 and zirconium phosphate sorbent module 402. A static mixer 409 can optionally be included to ensure complete mixing of solutions prior to entering the zirconium phosphate sorbent module 402 and can generate a dilute solution from the combined disinfectant solution and brine solution source 405 when a concentrated solution is used. One of skill in the art will understand that different pump and valve arrangements can be used with the system illustrated in FIG. 4. For example, the combined disinfectant solution and brine solution source 405 and water source 406 can be connected to the zirconium phosphate recharging flow path 401 through separate pumps, allowing simultaneous addition of water, brine, and disinfectant to the zirconium phosphate recharging flow path 401. A heater and/or heat exchanger (not shown) can be included for heating the combined disinfectant solution and brine solution and/or the rinse water prior to flowing the solutions through the zirconium phosphate sorbent module 402.


One skilled in the art will understand that various combinations and/or modifications and variations can be made in the described systems and methods depending upon the specific needs for operation. Moreover features illustrated or described as being part of an aspect of the invention may be used in the aspect of the invention, either alone or in combination.

Claims
  • 1. A method of recharging zirconium phosphate in a zirconium phosphate sorbent module, comprising the steps of: flowing a brine solution through the zirconium phosphate sorbent module; andflowing a disinfectant solution through the zirconium phosphate sorbent module after flowing the brine solution through the zirconium phosphate sorbent module.
  • 2. The method of claim 1, further comprising the step of flowing water through the zirconium phosphate sorbent module after the steps of flowing disinfectant solution and brine solution through the zirconium phosphate sorbent module.
  • 3. The method of claim 1, wherein the disinfectant solution is a peracetic acid solution and the brine solution contains acetic acid, sodium acetate, and sodium chloride.
  • 4. The method of claim 3, wherein the brine solution contains between 0 and 5.0 M sodium chloride, between 0.1 M and 2.0 M sodium acetate, and between 0.1 and 2.0 M acetic acid.
  • 5. The method of claim 3, wherein the disinfectant solution contains between 0.1 and 3.0 wt % peracetic acid or between 0.1 and 3.0 wt % peracetic acid and between 0.1 to 15 wt % acetic acid.
  • 6. The method of claim 1, wherein the the disinfectant solution and the brine solution are maintained at room temperature while flowing the the disinfectant solution and the brine solution through the zirconium phosphate sorbent module.
  • 7. The method of claim 1, wherein either or both of the disinfectant solution and the brine solution is maintained at room temperature for a set period of time, and then heated for a set period of time.
  • 8. The method of claim 1, wherein the step of flowing the disinfectant solution through the zirconium phosphate sorbent module comprises flowing a concentrated disinfectant solution and water to a static mixer to generate a dilute disinfectant solution; and flowing the dilute disinfectant solution through the zirconium phosphate sorbent module.
  • 9. The method of claim 1, wherein the step of flowing a brine solution through the zirconium phosphate sorbent module comprises flowing a concentrated brine solution and water to a static mixer to generate a dilute brine solution; and flowing the dilute brine solution through the zirconium phosphate sorbent module.
  • 10. The method of claim 1, further comprising the step of heating the brine solution to a temperature of between 70° C. and 100° C. prior to flowing the brine solution through the zirconium phosphate sorbent module.
  • 11. The method of claim 1, further comprising the step of rinsing the zirconium phosphate sorbent module with water prior to flowing the disinfectant solution through the zirconium phosphate sorbent module.
  • 12. The method of claim 1, further comprising the step of holding the disinfectant solution in the zirconium phosphate sorbent module.
  • 13. The method of claim 12, wherein the disinfectant solution is held in the zirconium phosphate sorbent module for between 0 and 30 minutes, between 5 and 10 minutes, between 5 and 15 minutes, between 10 and 20 minutes, between 15 and 30 minutes or between 20 and 30 minutes.
  • 14. The method of claim 12, further comprising the step of flowing disinfectant solution through the zirconium phosphate sorbent module at a flow rate of between 0 and 20 mL/min while holding the disinfectant solution in the zirconium phosphate sorbent module.
  • 15. The method of claim 12, further comprising the step of intermittently flowing fluid through the zirconium phosphate sorbent module while holding the disinfectant solution in the zirconium phosphate sorbent module.
  • 16. The method of claim 2, wherein the brine solution, the water, and the disinfectant solution are flowed through the zirconium phosphate sorbent module in a direction opposite to a flow direction during therapy.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of and priority to U.S. patent application Ser. No. 15/958,337 filed Apr. 20, 2018, which claims priority to Provisional Patent Application No. 62/519,933 filed Jun. 15, 2017, the entire disclosure of each of which is incorporated by reference herein.

US Referenced Citations (447)
Number Name Date Kind
1617288 Kenney Feb 1927 A
2703313 Gill Jan 1950 A
3608729 Haselden Sep 1971 A
3617545 Dubois Nov 1971 A
3617558 Jones Nov 1971 A
3669878 Marantz Jun 1972 A
3669880 Marantz Jun 1972 A
3776819 Williams Dec 1973 A
3840835 Kussy Oct 1974 A
3850835 Marantz Nov 1974 A
3884808 Scott May 1975 A
3902490 Jacobsen Sep 1975 A
3989622 Marantz Nov 1976 A
4060485 Eaton Nov 1977 A
4073725 Takeuchi Feb 1978 A
4094775 Mueller Jun 1978 A
4142845 Lepp Mar 1979 A
4192748 Hyden Mar 1980 A
4206054 Moore Jun 1980 A
4209392 Wallace Jun 1980 A
4269708 Bonomini May 1981 A
4371385 Johnson Feb 1983 A
4374382 Markowitz Feb 1983 A
4376707 Lehmann Mar 1983 A
4381999 Boucher May 1983 A
4460555 Thompson Jul 1984 A
4556063 Thompson Dec 1985 A
4562751 Nason Jan 1986 A
4581141 Ash Apr 1986 A
4612122 Ambrus Sep 1986 A
4650587 Polak Mar 1987 A
4661246 Ash Apr 1987 A
4678408 Mason Jul 1987 A
4684460 Issautier Aug 1987 A
4685903 Cable Aug 1987 A
4687582 Dixon Aug 1987 A
4750494 King Jun 1988 A
4765907 Scott Aug 1988 A
4826663 Alberti May 1989 A
4828693 Lindsay May 1989 A
5032615 Ward et al. Jul 1991 A
5047014 Mosebach et al. Sep 1991 A
5080653 Voss Jan 1992 A
5092886 Dobos-Hardy Mar 1992 A
5097122 Coiman Mar 1992 A
5127404 Wyborny Jul 1992 A
5192132 Pelensky Mar 1993 A
5230702 Lindsay Jul 1993 A
5284470 Beltz Feb 1994 A
5302288 Meidl Apr 1994 A
5305745 Zacouto Apr 1994 A
5308315 Khuri May 1994 A
5318750 Lascombes Jun 1994 A
5399157 Goux Mar 1995 A
5441049 Masano Aug 1995 A
5442969 Troutner Aug 1995 A
5445610 Evert Aug 1995 A
5468388 Goddard Nov 1995 A
5507723 Keshaviah Apr 1996 A
5662806 Keshaviah et al. Sep 1997 A
5683432 Goedeke Nov 1997 A
5685988 Malchesky Nov 1997 A
5716400 Davidson Feb 1998 A
5744031 Bene Apr 1998 A
5762782 Kenley Jun 1998 A
5770086 Indriksons Jun 1998 A
5849179 Emerson Dec 1998 A
5858186 Glass Jan 1999 A
5938634 Packard Aug 1999 A
5938938 Bosetto Aug 1999 A
5944684 Roberts Aug 1999 A
6036858 Carlsson Mar 2000 A
6048732 Anslyn Apr 2000 A
6052622 Holmstrom Apr 2000 A
6058331 King May 2000 A
6114176 Edgson et al. Sep 2000 A
6126831 Goldau Oct 2000 A
6171480 Lee Jan 2001 B1
6176003 Aoyama Jan 2001 B1
6230059 Duffin May 2001 B1
6248093 Moberg Jun 2001 B1
6254567 Treu Jul 2001 B1
6321101 Holmstrom Nov 2001 B1
6362591 Moberg Mar 2002 B1
6363279 Ben-Haim et al. Mar 2002 B1
6390969 Bolling et al. May 2002 B1
6491993 Forbes Dec 2002 B1
6521184 Edgson et al. Feb 2003 B1
6554798 Mann Apr 2003 B1
6555986 Moberg Apr 2003 B2
6565525 Burbank et al. May 2003 B1
6572769 Rajan Jun 2003 B2
6579460 Willis Jun 2003 B1
6585675 O'Mahony et al. Jul 2003 B1
6589229 Connelly Jul 2003 B1
6593747 Puskas Jul 2003 B2
6596234 Schnell et al. Jul 2003 B1
6602399 Fromherz Aug 2003 B1
6627164 Wong Sep 2003 B1
6666840 Falkvall et al. Dec 2003 B1
6676608 Keren Jan 2004 B1
6695807 Bell et al. Feb 2004 B2
6711439 Bradley Mar 2004 B1
6719745 Taylor Apr 2004 B1
6773412 O'Mahony et al. Aug 2004 B2
6814724 Taylor Nov 2004 B2
6818196 Wong Nov 2004 B2
6861266 Sternby Mar 2005 B1
6878258 Hughes Apr 2005 B2
6878283 Thompson Apr 2005 B2
6878285 Hughes Apr 2005 B2
6890315 Levin May 2005 B1
6923782 O'Mahony et al. Aug 2005 B2
6960179 Gura Nov 2005 B2
7029456 Ware et al. Apr 2006 B2
7033498 Wong Apr 2006 B2
7077819 Goldau Jul 2006 B1
7097630 Gotch Aug 2006 B2
7101519 Wong Sep 2006 B2
7128750 Stergiopulos Oct 2006 B1
7153693 Tajiri Dec 2006 B2
7208092 Micheli Apr 2007 B2
7241272 Karoor Jul 2007 B2
7276042 Polaschegg Oct 2007 B2
7309323 Gura Dec 2007 B2
7318892 Connell Jan 2008 B2
7326576 Womble et al. Feb 2008 B2
7384543 Jonsson et al. Jun 2008 B2
7435342 Tsukamoto Oct 2008 B2
7462161 O'Mahony et al. Dec 2008 B2
7488447 Sternby Feb 2009 B2
7537688 Tarumi May 2009 B2
7544300 Brugger Jun 2009 B2
7544737 Poss Jun 2009 B2
7563240 Gross Jul 2009 B2
7566432 Wong Jul 2009 B2
7575564 Childers Aug 2009 B2
7597806 Uchi Oct 2009 B2
7674231 McCombie Mar 2010 B2
7674237 O'Mahony et al. Mar 2010 B2
7686778 Burbank et al. Mar 2010 B2
7704361 Garde Apr 2010 B2
7736507 Wong Jun 2010 B2
7754852 Burnett Jul 2010 B2
7756572 Fard Jul 2010 B1
7776001 Brugger et al. Aug 2010 B2
7776006 Childers Aug 2010 B2
7776210 Rosenbaum Aug 2010 B2
7794141 Perry Sep 2010 B2
7794419 Paolini Sep 2010 B2
7850635 Polaschegg Dec 2010 B2
7867214 Childers Jan 2011 B2
7901376 Steck et al. Mar 2011 B2
7905853 Chapman et al. Mar 2011 B2
7922686 Childers Apr 2011 B2
7922911 Micheli Apr 2011 B2
7947179 Rosenbaum May 2011 B2
7955289 O'Mahony et al. Jun 2011 B2
7955290 Karoor Jun 2011 B2
7967022 Grant Jun 2011 B2
7981082 Wang Jul 2011 B2
7988854 Tsukamoto Aug 2011 B2
8002726 Karoor Aug 2011 B2
8012118 Curtin Sep 2011 B2
8029454 Kelly Oct 2011 B2
8034161 Gura Oct 2011 B2
8066658 Karoor Nov 2011 B2
8070709 Childers Dec 2011 B2
8080161 Ding et al. Dec 2011 B2
8087303 Beavis Jan 2012 B2
8096969 Roberts Jan 2012 B2
8180574 Lo May 2012 B2
8182673 Childers et al. May 2012 B2
8183046 Lu May 2012 B2
8187250 Roberts May 2012 B2
8197439 Wang Jun 2012 B2
8206591 Kotanko et al. Jun 2012 B2
8211048 Szamosfalvi et al. Jul 2012 B2
8221529 Childers et al. Jul 2012 B2
8226595 Childers et al. Jul 2012 B2
8246826 Wilt Aug 2012 B2
8267881 O'Mahony et al. Sep 2012 B2
8273049 Demers Sep 2012 B2
8292594 Tracey Oct 2012 B2
8303532 Hamada Nov 2012 B2
8313642 Yu Nov 2012 B2
8317492 Demers Nov 2012 B2
8357113 Childers Jan 2013 B2
8357298 Demers et al. Jan 2013 B2
8366316 Kamen Feb 2013 B2
8366655 Kamen Feb 2013 B2
8376999 Busby et al. Feb 2013 B2
8377012 Chapman et al. Feb 2013 B2
8377308 Kreymann et al. Feb 2013 B2
8388567 Rovatti Mar 2013 B2
8404491 Li Mar 2013 B2
8409441 Wilt Apr 2013 B2
8409444 Wong Apr 2013 B2
8449487 Wallenborg et al. May 2013 B2
8480607 Davies Jul 2013 B2
8499780 Wilt Aug 2013 B2
8518260 Raimann Aug 2013 B2
8535525 Heyes Sep 2013 B2
8580112 Updyke Nov 2013 B2
8597227 Childers Dec 2013 B2
8647506 Wong Feb 2014 B2
8696626 Kirsch Apr 2014 B2
8733559 Wong May 2014 B2
8764981 Ding Jul 2014 B2
8777892 Sandford Jul 2014 B2
8903492 Soykan Dec 2014 B2
9144640 Pudil Sep 2015 B2
9254355 Sandford Feb 2016 B2
9527015 Chau Dec 2016 B2
20010007931 Blatter Jul 2001 A1
20010009756 Hei et al. Jul 2001 A1
20020016550 Sweeney Feb 2002 A1
20020027106 Smith Mar 2002 A1
20020042561 Schulman Apr 2002 A1
20020062098 Cavicchioli et al. May 2002 A1
20020112609 Wong Aug 2002 A1
20020117436 Rajan Aug 2002 A1
20030080059 Peterson May 2003 A1
20030097086 Gura May 2003 A1
20030105435 Taylor Jun 2003 A1
20030113931 Pan Jun 2003 A1
20030114787 Gura Jun 2003 A1
20030138348 Bell et al. Jul 2003 A1
20030187479 Thong Oct 2003 A1
20040019312 Childers Jan 2004 A1
20040019320 Childers Jan 2004 A1
20040030277 O'Mahony et al. Feb 2004 A1
20040037986 Houston et al. Feb 2004 A1
20040054315 Levin et al. Mar 2004 A1
20040082903 Micheli Apr 2004 A1
20040084358 O'Mahony et al. May 2004 A1
20040099593 DePaolis May 2004 A1
20040147900 Polaschegg Jul 2004 A1
20040168963 King Sep 2004 A1
20040215090 Erkkila Oct 2004 A1
20040257409 Cheok Dec 2004 A1
20050006296 Sullivan Jan 2005 A1
20050056592 Braunger Mar 2005 A1
20050065760 Murtfeldt Mar 2005 A1
20050101901 Gura May 2005 A1
20050113796 Taylor May 2005 A1
20050126961 Bissler Jun 2005 A1
20050131332 Kelly Jun 2005 A1
20050126998 Childers Jul 2005 A1
20050148923 Sternby Jul 2005 A1
20050150832 Tsukamoto Jul 2005 A1
20050230313 O'Mahony et al. Oct 2005 A1
20050234354 Rowlandson Oct 2005 A1
20050234381 Niemetz Oct 2005 A1
20050274658 Rosenbaum Dec 2005 A1
20060025661 Sweeney Feb 2006 A1
20060037483 Kief Feb 2006 A1
20060217771 Soykan Feb 2006 A1
20060157413 Bene Jul 2006 A1
20060189926 Hall et al. Aug 2006 A1
20060195064 Plahey Aug 2006 A1
20060226079 Mori Oct 2006 A1
20060241543 Gura Oct 2006 A1
20060241709 Soykan Oct 2006 A1
20060264894 Moberg Nov 2006 A1
20070007208 Brugger et al. Jan 2007 A1
20070055296 Stergiopulos Mar 2007 A1
20070066928 Lannoy Mar 2007 A1
20070138011 Hofmann Jun 2007 A1
20070175827 Wariar Aug 2007 A1
20070179431 Roberts Aug 2007 A1
20070213665 Curtin Sep 2007 A1
20070215545 Bissler Sep 2007 A1
20070243113 DiLeo Oct 2007 A1
20070255250 Moberg Nov 2007 A1
20080006570 Gura Jan 2008 A1
20080011664 Karoor Jan 2008 A1
20080015493 Childers et al. Jan 2008 A1
20080021337 Li Jan 2008 A1
20080051696 Curtin Feb 2008 A1
20080053905 Brugger Mar 2008 A9
20080067132 Ross Mar 2008 A1
20080215247 Tonelli Sep 2008 A1
20080217245 Rambod Sep 2008 A1
20080241031 Li Oct 2008 A1
20080292935 Roelofs Nov 2008 A1
20090012864 Goldberg Jan 2009 A1
20090020471 Tsukamoto Jan 2009 A1
20090078636 Uchi Mar 2009 A1
20090084199 Wright Apr 2009 A1
20090101552 Fulkerson Apr 2009 A1
20090101577 Fulkerson Apr 2009 A1
20090120864 Fulkerson May 2009 A1
20090127193 Updyke May 2009 A1
20090149795 O'Mahony et al. Jun 2009 A1
20090216045 Singh Aug 2009 A1
20090266358 Sacristan Rock Oct 2009 A1
20090275849 Stewart Nov 2009 A1
20090275883 Chapman Nov 2009 A1
20090281484 Childers Nov 2009 A1
20090282980 Gura Nov 2009 A1
20100004588 Yeh Jan 2010 A1
20100007838 Fujimoto Jan 2010 A1
20100010429 Childers Jan 2010 A1
20100018923 Rohde et al. Jan 2010 A1
20100030151 Kirsch Feb 2010 A1
20100051529 Grant et al. Mar 2010 A1
20100051552 Rohde Mar 2010 A1
20100076364 O'Mahony et al. Mar 2010 A1
20100078381 Merchant Apr 2010 A1
20100078387 Wong Apr 2010 A1
20100084330 Wong Apr 2010 A1
20100094158 Solem Apr 2010 A1
20100100027 Schilthuizen Apr 2010 A1
20100101195 Clements Apr 2010 A1
20100102190 Zhu et al. Apr 2010 A1
20100114001 O'Mahony May 2010 A1
20100114012 Sandford May 2010 A1
20100137693 Porras Jun 2010 A1
20100168546 Kamath Jul 2010 A1
20100168641 O'Mahony et al. Jul 2010 A1
20100213127 Castellarnau Aug 2010 A1
20100217181 Roberts Aug 2010 A1
20100224492 Ding Sep 2010 A1
20100234795 Wallenas Sep 2010 A1
20100241045 Kelly Sep 2010 A1
20100252490 Fulkerson Oct 2010 A1
20100312172 Hoffman Dec 2010 A1
20100312174 Hoffman Dec 2010 A1
20100314314 Ding Dec 2010 A1
20100326911 Rosenbaum Dec 2010 A1
20110009798 Kelly Jan 2011 A1
20110017665 Updyke Jan 2011 A1
20110048949 Ding et al. Mar 2011 A1
20110066043 Banet Mar 2011 A1
20110077574 Sigg Mar 2011 A1
20110079558 Raimann Apr 2011 A1
20110087187 Beck Apr 2011 A1
20110130666 Dong Jun 2011 A1
20110163034 Castellarnau Jul 2011 A1
20110171713 Bluchel Jul 2011 A1
20110184340 Tan Jul 2011 A1
20110220562 Beiriger Sep 2011 A1
20110247973 Sargand Oct 2011 A1
20110272337 Palmer Nov 2011 A1
20110272352 Braig Nov 2011 A1
20110297593 Kelly Dec 2011 A1
20110315611 Fulkerson Dec 2011 A1
20110315632 Freije Dec 2011 A1
20120016228 Kroh Jan 2012 A1
20120018377 Tsukamoto Jan 2012 A1
20120083729 Childers Apr 2012 A1
20120085707 Beiriger Apr 2012 A1
20120092025 Volker Apr 2012 A1
20120095402 Lande Apr 2012 A1
20120115248 Ansyln May 2012 A1
20120220528 VanAntwerp Aug 2012 A1
20120248017 Beiriger Oct 2012 A1
20120258545 Ash Oct 2012 A1
20120258546 Marran Oct 2012 A1
20120273354 Orhan et al. Nov 2012 A1
20120273415 Gerber Nov 2012 A1
20120273420 Gerber Nov 2012 A1
20120277546 Soykan Nov 2012 A1
20120277551 Gerber Nov 2012 A1
20120277552 Gerber Nov 2012 A1
20120277604 Gerber Nov 2012 A1
20120277650 Gerber Nov 2012 A1
20120277655 Gerber Nov 2012 A1
20120277722 Gerber Nov 2012 A1
20120303079 Mahajan Nov 2012 A1
20130006128 Olde et al. Jan 2013 A1
20130018095 Vath Jan 2013 A1
20130019179 Zhao Jan 2013 A1
20130020237 Wilt et al. Jan 2013 A1
20130023812 Hasegawa et al. Jan 2013 A1
20130025357 Noack et al. Jan 2013 A1
20130027214 Eng Jan 2013 A1
20130028809 Barton Jan 2013 A1
20130030347 Sugioka Jan 2013 A1
20130030348 Lauer Jan 2013 A1
20130030356 Ding Jan 2013 A1
20130037142 Farrell Feb 2013 A1
20130037465 Heyes Feb 2013 A1
20130056418 Kopperschmidt et al. Mar 2013 A1
20130072895 Kreischer et al. Mar 2013 A1
20130075314 Nikolic Mar 2013 A1
20130087210 Brandl et al. Apr 2013 A1
20130110028 Bachmann et al. May 2013 A1
20130116578 An May 2013 A1
20130199998 Kelly Aug 2013 A1
20130213890 Kelly Aug 2013 A1
20130213891 Karoor Aug 2013 A1
20130228516 Jonsson Sep 2013 A1
20130274642 Soykan Oct 2013 A1
20130324915 (Krensky)Britton Dec 2013 A1
20130330208 Ly Dec 2013 A1
20130331774 Farrell Dec 2013 A1
20140001112 Karoor Jan 2014 A1
20140018728 Plahey Jan 2014 A1
20140042092 Akonur Feb 2014 A1
20140065950 Mendelsohn Mar 2014 A1
20140088442 Soykan Mar 2014 A1
20140110340 White Apr 2014 A1
20140110341 White Apr 2014 A1
20140138294 Fulkerson May 2014 A1
20140158538 Collier Jun 2014 A1
20140158588 Pudil Jun 2014 A1
20140158623 Pudil Jun 2014 A1
20140190876 Meyer Jul 2014 A1
20140190885 Meyer Jul 2014 A1
20140190886 Pudil Jul 2014 A1
20140190891 Lura Jul 2014 A1
20140217028 Pudil Aug 2014 A1
20140217030 Meyer Aug 2014 A1
20140220699 Pudil Aug 2014 A1
20140251908 Ding Sep 2014 A1
20140262812 Longhenry Sep 2014 A1
20140326671 Kelly Nov 2014 A1
20140336568 Wong Nov 2014 A1
20150057602 Mason Feb 2015 A1
20150108069 Merchant Apr 2015 A1
20150108609 Kushida Apr 2015 A1
20150114891 Meyer Apr 2015 A1
20150144539 Pudil May 2015 A1
20150144542 Pudil May 2015 A1
20150157960 Pudil Jun 2015 A1
20150238673 Gerber Aug 2015 A1
20150250937 Pudil Sep 2015 A1
20150251161 Pudil Sep 2015 A1
20150251162 Pudil Sep 2015 A1
20150258266 Merchant Sep 2015 A1
20150306292 Pudil Oct 2015 A1
20150367051 Gerber Dec 2015 A1
20150367052 Gerber Dec 2015 A1
20150367055 Pudil Dec 2015 A1
20150367056 Gerber Dec 2015 A1
20150367057 Gerber Dec 2015 A1
20150367058 Gerber Dec 2015 A1
20150367059 Gerber Dec 2015 A1
20150367060 Gerber Dec 2015 A1
20160236188 Menon Aug 2016 A1
20160243299 Gerber Aug 2016 A1
20160243540 Menon Aug 2016 A1
20160243541 Menon Aug 2016 A1
20170087533 Hobot Mar 2017 A1
20180221852 Pudil Aug 2018 A1
Foreign Referenced Citations (142)
Number Date Country
1487853 Apr 2004 CN
102573618 Jul 2012 CN
102762268 Oct 2012 CN
103402563 Nov 2013 CN
103747818 Apr 2014 CN
103889478 Jun 2014 CN
104936633 Sep 2015 CN
105992599 May 2016 CN
105658326 Jun 2016 CN
106413878 Feb 2017 CN
3110128 Sep 1982 DE
102011052188 Jan 2013 DE
0266795 Nov 1987 EP
0264695 Apr 1988 EP
0614081 Jul 2000 EP
1085295 Nov 2001 EP
711182 Jun 2003 EP
1364666 Nov 2003 EP
0906768 Feb 2004 EP
1450879 Oct 2008 EP
1991289 Nov 2008 EP
1592494 Jun 2009 EP
2100553 Sep 2009 EP
2575827 Dec 2010 EP
2576453 Dec 2011 EP
2446908 May 2012 EP
2701580 Nov 2012 EP
2701595 Nov 2012 EP
1545652 Jan 2013 EP
1684625 Jan 2013 EP
2142234 Jan 2013 EP
2550984 Jan 2013 EP
1345856 Mar 2013 EP
1938849 Mar 2013 EP
2219703 Mar 2013 EP
2564884 Mar 2013 EP
2564885 Mar 2013 EP
2344220 Apr 2013 EP
1345687 Jun 2013 EP
2701596 Mar 2014 EP
2950836 Dec 2015 EP
3546042 Oct 2019 EP
3626280 Mar 2020 EP
S5070281 Jun 1975 JP
S51-55193 May 1976 JP
S51-131393 Nov 1976 JP
S61164562 Jul 1986 JP
2981573 Nov 1999 JP
2005511250 Apr 2005 JP
H4-90963 May 2005 JP
2007-44602 Feb 2007 JP
200744602 Feb 2007 JP
200744602 Feb 2007 JP
5-99464 Oct 2012 JP
2013502987 Oct 2013 JP
1701752 Sep 2006 WF
9106326 May 1991 WO
9532010 Nov 1995 WO
9937342 Jul 1999 WO
2000038591 Jul 2000 WO
0057935 Oct 2000 WO
200066197 Nov 2000 WO
200170307 Sep 2001 WO
2001085295 Sep 2001 WO
0185295 Nov 2001 WO
2002043859 Jun 2002 WO
200303677 May 2003 WO
2003043680 May 2003 WO
WO 2003041764 May 2003 WO
2003051422 Jun 2003 WO
2004008826 Jan 2004 WO
2004009156 Jan 2004 WO
2004030716 Apr 2004 WO
2004030717 Apr 2004 WO
2004064616 Aug 2004 WO
2004062710 Oct 2004 WO
WO 2005062973 Jul 2005 WO
2005123230 Dec 2005 WO
2007089855 Aug 2007 WO
WO 20070103411 Sep 2007 WO
2008075951 Jun 2008 WO
2009026603 Dec 2008 WO
2009064984 May 2009 WO
2009157877 Dec 2009 WO
2009157878 Dec 2009 WO
20090157877 Dec 2009 WO
2010028860 Mar 2010 WO
2010102190 Nov 2010 WO
2010141949 Dec 2010 WO
WO 2011017215 Feb 2011 WO
2011025705 Mar 2011 WO
2012148781 Nov 2012 WO
2012148786 Nov 2012 WO
2012148789 Nov 2012 WO
2012162515 Nov 2012 WO
2012172398 Dec 2012 WO
2013019179 Feb 2013 WO
2013019994 Feb 2013 WO
2013022024 Feb 2013 WO
2013022837 Feb 2013 WO
2013025844 Feb 2013 WO
2013025957 Feb 2013 WO
2013027214 Feb 2013 WO
2013028809 Feb 2013 WO
WO 2013019179 Feb 2013 WO
WO 2013019994 Feb 2013 WO
WO 2013-025957 Feb 2013 WO
WO 2013028809 Feb 2013 WO
WO 2013019179 Feb 2013 WO
WO2014121238 Feb 2013 WO
2013030642 Mar 2013 WO
2013030643 Mar 2013 WO
2012060700 May 2013 WO
2013101888 Jul 2013 WO
2013103607 Jul 2013 WO
2013103906 Jul 2013 WO
WO 2013103607 Jul 2013 WO
WO 2013109922 Jul 2013 WO
2013114063 Aug 2013 WO
2013121162 Aug 2013 WO
14066254 May 2014 WO
14066255 May 2014 WO
14077082 May 2014 WO
2014121162 Aug 2014 WO
2014121163 Aug 2014 WO
2014121167 Aug 2014 WO
2014121169 Aug 2014 WO
2015060914 Apr 2015 WO
WO 2015080895 Apr 2015 WO
WO 2015060914 Apr 2015 WO
WO 2015126879 Aug 2015 WO
2015142624 Sep 2015 WO
2015199764 Dec 2015 WO
2015199765 Dec 2015 WO
2015199863 Dec 2015 WO
2015199864 Dec 2015 WO
WO 2015-199863 Dec 2015 WO
WO 2015-199864 Dec 2015 WO
WO 2015199765 Dec 2015 WO
WO 2016191039 Dec 2016 WO
WO 2016191041 Dec 2016 WO
WO 2013-028809 Feb 2018 WO
Non-Patent Literature Citations (210)
Entry
Brynda, et al., The detection of toman 2-microglcbuiin by grating coupler immunosensor with three dimensional antibody networks. Biosensors & Bioelectronics, 1999, 363-368, 14(4).
Wheaton, et al., Dowex Ion Exchange Resins-Fundamentals of Ion Exchange; Jun. 2000, pp. 1-9. http://www.dow.com/scripts/litorder.asp?filepath=liquidseps/pdfs/noreg/177-01837.pdf.
Zhong, et al., Miniature urea sensor based on H(+)-ion sensitive field effect transistor and its application in clinical analysis, Chin. J. Biotechnol., 1992, 57-65. 8(1).
PCT/US2012/034331, International Search Report and Written Opinion dated Jul. 9, 2012.
Roberts M, The regenerative dialysis (REDY) sorbent system. Nephrology, 1998, 275-278:4.
U.S. Appl. No. 61/480,544, dated Apr. 29, 2011.
U.S. Appl. No. 61/480,541 dated Apr. 29, 2011.
Hemametrics, Crit-Line Hematocrit Accuracy, 2003, 1-5, vol. 1, Tech Note No. 11 (Rev. D).
Weissman, S., et al., Hydroxyurea-induced hepatitis in human immunodeficiency virus-positive patients. Clin. Infec. Dis, (Jul. 29, 1999): 223-224.
PCT/US2012/034334, International Search Report, dated Jul. 6, 2012.
PCT/US2012/034335, International Search Report, dated Sep. 5, 2012.
PCT/US/2012/034327, International Search Report, dated Aug. 13, 2013.
PCT/US/2012/034329, International Search Report, dated Dec. 3, 2012.
International Search Report from PCT/US2012/051946 dated Mar. 4, 2013.
U.S. Appl. No. 61/526,209.
Wang, Fundamentals of intrathoracic impedance monitoring in heart failure, Am. J. Cardiology, 2007, 3G-10G: Suppl.
PCT/US2014/067650 International Search Report Written Opinion dated Mar. 9, 2015.
Bleyer, et al., Sudden and cardiac death rated in hemodialysis patients, Kidney International. 1999, 1553-1559: 55.
PCT/US2012/034333, International Preliminary Report on Patentability, dated Oct. 29, 2013.
PCT/US2012/034333, International Search Report, dated Aug. 29, 2012.
PCT/US2012/034330, International Preliminary Report on Patentability, dated Oct. 29, 2013.
PCT/US2014/065950 International Search Report and Written Opinion dated Feb. 24, 2015.
Culleton, BF et al. Effect of Frequent Nocturnal Hemodialysis vs. Conventional Hemodialysis on Left Ventricular Mass and Quality of Life. 2007 Journal of the American Medical Association 298 (11), 1291-1299.
U.S. Appl. No. 13/757,722, filed Feb. 1, 2013.
U.S. Appl. No. 13/757,794, filed Feb. 2, 2012.
U.S. Appl. No. 13/791,755, filed Mar. 8, 2013.
U.S. Appl. No. 13/424,479 dated Nov. 1, 2012.
U.S. Appl. No. 13/757,792, filed Feb. 2, 2013.
U.S. Appl. No. 13/757,794, filed Feb. 2, 2013.
U.S. Appl. No. 13/837,287, filed Mar. 15, 2013.
U.S. Appl. No. 13/424,429 dated Nov. 1, 2012.
Redfield, et al., Restoration of renal response to atrial natriuretic factor in experimental low-output heat failure, Am. J. Physiol., Oct. 1, 1989, R917-923:257.
Rogoza, et al., Validation of A&D UA-767 device for the self-measurement of blood pressure, Blood Pressure Monitoring, 2000, 227-231, 5(4).
Lima, et al., An electrochemical sensor based on nanostructure hollandite-type manganese oxide for detection of potassium ion, Sensors, Aug. 24, 2009, 6613-8625, 9.
MacLean, et, al., Effects of hindlimb contraction on pressor and muscle interstitial metabolite responses in the cat, J. App. Physiol., 1998, 1583-1592, 85(4).
U.S. Appl. No. 13/757,693, dated Feb. 1, 2013.
PCT Application, PCT/US2013/020404, filed Jan. 4, 2013.
U.S. Appl. No. 13/424,525, filed Nov. 1, 2012.
U.S. Appl. No. 13/836,973, filed Mar. 15, 2013.
U.S. Appl. No. 14/259,655, filed Apr. 23, 2014.
U.S. Appl. No. 14/259,589, filed Apr. 23, 2014.
U.S. Appl. No. 13/757,693, filed Jan. 4, 2013.
U.S. Appl. No. 13/836,079, filed Mar. 15, 2013.
U.S. Appl. No. 14/240,129, filed Aug. 22, 2013.
PCT/US2014/014346 International Search Report and Written Opinion.
U.S. Appl. No. 13/100,847, filed Nov. 10, 2011, C-Tech BioMedical Inc.
U.S. Appl. No. 13/565,733, filed Aug. 2, 2012, Medtronic.
U.S. Appl. No. 13/757,693, filed Feb. 1, 2013, Medtronic.
U.S. Appl. No. 13/757,709, Feb. 1, 2013, Medtronic.
U.S. Appl. No. 13/757,728, filed Feb. 1, 2013, Medtronic.
U.S. Appl. No. 13/836,538, filed Mar. 15, 2013, Medtronic.
U.S. Appl. No. 14/637,606_OA.
U.S. Appl. No. 14/645,394_OA.
U.S. Appl. No. 13/835,735, filed Mar. 15, 2013.
PCT/US2014/014345 International Search Report and Written Opinion, dated May 2014.
U.S. Appl. No. 13/835,735 IDS, filed Jun. 13, 2013.
PCT/US2014/014357 International Search Report and Written Opinion dated May 19, 2014.
Ronco et al. 2008, Cardiorenal Syndrome, Journal American College Cardiology, 52:1527-1539, Abstract.
Overgaard, et al., Activity-induced recovery of excitability in K+-depressed rat soleus muscle, Am. J. P 280: R48-R55, Jan. 1, 2001.
Overgaard et al., Relations between excitability and contractility in rate soleusmuscle: role of the NA+-K+ pump and NA+-K-S gradients. Journal of Physiology, 1999, 215-225, 518(1).
PCT/US2015/032492 International Search Report dated Nov. 19, 2015.
Coast, et al. 1990, An approach to Cardiac Arrhythmia analysis Using Hidden Markov Models, IEEE Transactions on Biomedical Engineering. 1990, 37(9):826-835.
U.S. Appl. No. 61/480,532, filed Apr. 29, 2011.
U.S. Appl. No. 61/480,530, filed Apr. 29, 2011.
U.S. Appl. No. 61/480,528 dated Apr. 29, 2011.
Secemsky, et al., High prevalence of cardiac autonomic dysfunction and T-wave alternans in dialysis patients. Heart Rhythm, Apr. 2011, 592-598 : vol. 8, No. 4.
Wei, et al., Fullerene-cryptand coated piezoelectric crystal urea sensor based on urease, Analytica Chimica Acta, 2001,77-85:437.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 1-140.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 141-280.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 281-420.
Gambro AK 96 Dialysis Machine Operators Manual, Dec. 2012. p. 421-534.
U.S. Appl. No. 13/368,225 dated Feb. 7, 2012.
Leifer et al., A Study on the Temperature Variation of Rise Velocity for Large Clean Bubbles, J. Atmospheric & Oceanic Tech., vol. 17, pp. 1392-1402, Oct. 2000.
Talaia, Terminal Velocity of a Bubble Rise in a Liquid Column, World Acad. of Sci., Engineering & Tech., vol. 28, pp. 264-268, Published Jan. 1, 2007.
The FHN Trial Group. In-Center. Hemodialysis Six Times per Week versus Three Times per Week, New England Journal of Medicine, 2010 Abstract.
Gotch FA, Sargent JA A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). Kidney int. 1985: 28:526-34.
Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V and analysis of error. J Am Soc Nephrol, 1993: 4:1205-13.
Steil et al. Intl Journ Artif Organs, 1993, In Vivo Verification of an Automatic Noninvasive System for Real Time Kt Evaluation, ASAIO J., 1993, 39:M348-52.
PCT/US2012/034332, International Search Report, dated Jul. 5, 2012.
PCT/US2015/019901 International Search Report and Written Opinion dated Jun. 5, 2015.
Siegenthaler, et al., Pulmonary fluid status monitoring with intrathoracic impedance, Journal of Clinical Monitoring and Computing, 24:449-451, published Jan. 12, 2011.
U.S. Appl. No. 61/480,544. unpublished.
John Wm Agar: Review: Understanding sorbent dialysis systems, Nephrology, vol. 15, No. 4, Jun. 1, 2010, pp. 406-411.
EP. App. 14746193.3 Search Report dated Oct. 19, 2016.
PCT/US2015/016270 International Search Report and Written Opinion dated Jun. 5, 2015.
Office Action in U.S. Appl. No. 14/269,589, dated Nov. 4, 2016.
Office Action in U.S. Appl. No. 13/586,824 dated Dec. 21, 2015.
Office Action in U.S. Appl. No. 13/586,824 dated Jun. 4, 2015.
Eureopean Search Report for App. No. EP14745643 dated Oct. 6, 2016.
PCT/US15/18587 International Preliminary Report on Patentability dated Jun. 6, 2016.
European Search Opinion for App. No. EP12826180 dated Mar. 19, 2015.
European Search Opinion for App. No. EP12826180 dated Jan. 18, 2016.
Khanna, Ramesh, R.T. Krediet, and Karl D. Nolph. Nolph and Gokals Textbook of Peritoneal Dialysis New York: Springer 2009. Print.
Ruperez et al., Comparison of a tubular pulsatile pump and a volumetric pump for continuous venovenous renal replacement therapy in a pediatric animal model, 51 ASAIO J. 372, 372-375 (2005).
St. Peter et al., Liver and kidney preservation by perfusion, 359 The Lancet 604, 606(2002).
Dasselaar et al., Measurement of relative blood volume changes during hemodialysis: merits and limitations, 20 Nephrol Dial Transpl. 2043, 2043-2044 (2005).
Ralph T. Yang, Adsorbents: Fundamentals and Applications 109 (2003).
Henny H. Billett, Hemoglobin and Hematocrit, in Clinical Methods: The History, Physical, and Laboratory Examinations 719(HK Walker, WD Hall, & JW Hurst ed., 1990).
Office Action in U.S. Appl. No. 13/565,733 dated Jan. 11, 2016.
Office Action in U.S. Appl. No. 13/565,733 dated Jun. 11, 2015.
U.S. Appl. No. 13/424,454, dated Nov. 1, 2012.
Office Action in U.S. Appl. No. 13/757,792 dated Jun. 2, 2016.
Office Action in U.S. Appl. No. 13/757,796 dated Apr. 13, 2015.
Office Action in U.S. Appl. No. 13/757,796 dated Dec. 21, 2015.
Office Action in U.S. Appl. No. 13/835,735 dated Oct. 13, 2015.
Office Action in U.S. Appl. No. 13/836,079 dated Jun. 30, 2016.
Office Action in U.S. Appl. No. 13/791,755 dated Mar. 16, 2016.
Office Action in U.S. Appl. No. 13/791,755 dated Aug. 9, 2016.
Office Action in U.S. Appl. No. 13/835,735 dated Jun. 16, 2016.
Office Action in U.S. Appl. No. 13/836,079 dated Nov. 6, 2015.
U.S. Appl. No. 13/424,467, filed Nov. 1, 2012.
Office Action in App. No. AU 2015280604 dated Apr. 8, 2016.
International Search Report from International Application No. PCT/US2014/014347 dated May 9, 2014.
PCT/US2016/030319 Written Opinion dated Jul. 27, 2016.
PCT/US2016/030320 Written Opinion dated Jul. 27, 2016.
PCT/US2012/014347, International Search Report.
PCT/US2015/016273 International Search Report and Written Opinion dated Jun. 9, 2015.
Wester et al., A regenerable postassium and phosphate sorbent system to enhance dialysis efficacy and device portability: an in vitro study Nephrol Dial Transplant (2013) 28: 2364-2371 Jul. 3, 2013.
Office Action in App. No. JP 2016-515476 dated Dec. 26, 2016.
Japanese Patent Publication No. S50-70281A.
PCT/US2015/032494 Written Opinion dated Nov. 19, 2015.
PCT/US2015/032494 International Search Report dated Nov. 19, 2015.
PCT/US2015/019901 International Preliminary Report on Patentability dated May 27, 2016.
PCT/US2015/019901 Written Opinion dated May 27, 2016.
PCT/US2015/019901 Written Opinion dated Jun. 5, 2015.
PCT/US2015/019901 International Search Report dated Jun. 5, 2015.
PCT/US2015/032485 International Preliminary Report on Patentability dated May 11, 2016.
PCT/US20115/032485 International Preliminary Report on Patentability dated May 11, 2016.
PCT/US2016/030304 International Search Report dated Jul. 27, 2016.
PCT/US2016/030304 Written Opinion dated Jul. 27, 2016.
PCT/US2016/030312 Written Opinion dated Jul. 28, 2016.
PCT/US2016/030312 International Search Report dated Jul. 28, 2016.
PCT/US2016/030319 International Search Report dated Jul. 27, 2016.
PCT/US2016/030320 Written Opinion dated Jul. 28, 2016.
PCT/US2016/030320 International Search Report dated Jul. 28, 2016.
PCT/US2015/032485 Written Opinion dated Oct. 16, 2015.
PCT/US2015/032485 Written Opinion dated Oct. 16, 2016.
PCT/US2015/032485 International Search Report and Written Opinion dated Oct. 16, 2015.
U.S. Appl. No. 13/424,533, dated Nov. 1, 2012.
PCT/US2016/030320 International Preliminary Report on Patentability, dated Apr. 20, 2017.
International Preliminary Report from International Application No. PCT/US2014/014348 dated Jan. 9, 2015.
European Search Report from European Application No. EP 14746193.3 dated Oct. 19, 2016.
European Search Report from European Application No. EP 14746193.3 dated Jun. 8, 2016.
PCT/US2014/014345 Written Opinion dated Jun. 24, 2015.
PCT/US2014/014345 International Search Report and Written Opinion dated May 30, 2014.
Office Action in European Application No. 14746428.03 dated Feb. 8, 2017.
European Search Report in European Application No. 14746428.03 dated Aug. 25, 2016.
PCT/US2014/014346 Writtent Opinion dated Apr. 10, 2015.
PCT/US2014/014346 International Search Report and Writtent Opinion dated May 23, 2014.
EP 14746415.0 European Search Report dated Aug. 22, 2016.
Office Action in European Application No. EP 14746415.0 dated Apr. 19, 2017.
Office Action in European Application No. 14746415.0 dated Apr. 19, 2017.
U.S. Appl. No. 13/424,490, filed Nov. 1, 2012.
PCT/US2015/020047 International Search Report and Written Opinion dated Jun. 29, 2015.
PCT/US2015/020047 International Preliminary Report on Patentability dated Jun. 30, 2015.
PCT/US2015/020044 Written Opinion dated Jun. 21, 2016.
PCT/US2015/020044 International Preliminary Report on Patentability dated Nov. 4, 2016.
PCT/US2015/020044 International Search Report dated Jun. 30, 2015.
US2015/019881 Written Opinion dated Jun. 16, 2016.
US2015/019881 Written Opinion dated May 9, 2016.
U.S. Appl. No. 13/424,517, dated Nov. 1, 2012.
US2015/019881 International Search Report and Written Opinion dated Jun. 29, 2015.
PCT/US2014/065950 International Preliminary Report on Patentability dated Oct. 28, 2015.
PCT/US2015/032485 Written Opinion dated May 9, 2016.
PCT/US2015/032492 Written Opinion dated Nov. 19, 2015.
PCT/US2015/032494 International Preliminary Report on Patentablity dated Dec. 27, 2016.
Office Action for Chinese Application No. 201580009562.5 dated Jul. 3, 2017.
International Preliminary Report on Patentability for Application No. PCT/US2015/032492 dated Jun. 30, 2017.
Office Action in European Application No. 14746193.3 dated Apr. 19, 2017.
International Preliminary Report on Patentability for Application No. PCT/US2015/016273 dated Feb. 19, 2016.
European Search Report for App. No. 15751391.2 dated Aug. 4, 2017.
European Search Report and supplementary Search Report for App. No.14865374.4 dated Jun. 12, 2017.
European Search Report and Supplemental Search Report in European Application No. 14865374.4 dated Jun. 12, 2017.
PCT/US2015/020046 International Search Report and Written Opinion dated Jun. 29, 2015.
U.S. Appl. No. 61/480,539 dated Apr. 29, 2011.
U.S. Appl. No. 61/480,535 dated Apr. 29, 2011.
PCT/US2015/020044 International Search Report Written Opinion dated Jun. 30, 2015.
Nedelkov, et. al., Design of buffer exchange surfaces and sensor chips for biosensor chip mass spectrometry, Proteomics, 2002, 441-446, 2(4).
European Search Report App 14865374.4, dated Jun. 12, 2017.
Chinese Office Action for App. No. 201711179516.7, dated Feb. 19, 2020.
Chinese Office Action for App. No. 201711179528.X, dated Jul. 27, 2020.
Chinese Office Action for App. No. 201711179528.X, dated Mar. 26, 2020.
Chinese Office Action for App. No. 201810580243.5, dated Jul. 3, 2020.
Chinese Office Action in App. No. 201580009563.X, dated Mar. 13, 2018.
European Search Report for App. No. 15812081.6, dated Mar. 8, 2018.
European Search Report for App. No. 18153940.4, dated Jun. 12, 2018.
European Search Report for App. No. 18153940.4, dated Sep. 28, 2018.
European Search Report for App. No. 19191469.6, dated Jan. 8, 2020.
European Search Report for App. No. 19197167.0, dated Jan. 30, 2020.
European Search Report for App. No. 20158130.3, dated Jul. 8, 2020.
European Search Report for App. No. 20164524.9, dated Aug. 21, 2020.
European Search Report for EP 15811439, dated Feb. 15, 2018.
European Search Report for EP App. No. 15810804.3, dated Feb. 15, 2018.
European Search Report for EP App. No. 15811326.6, dated Feb. 14, 2018.
European Search Report for EP App. No. 15811573.3, dated Feb. 15, 2018.
European Search Report for EP App. No. 15812413.1, dated Feb. 2, 2018.
European Search Report for EP18177673.3-1104 (dated Oct. 19, 2018).
European Search Report for EP18177683.2-1104 (dated Nov. 8, 2018).
European Search Report in EP 15811454, dated Feb. 15, 2018.
European Search Report in EP 15812559.1, dated Jan. 31, 2018.
Office Action for Chinese App. No. 201711179516.7, dated Sep. 11, 2019.
Office Action for Chinese App. No. 201810042927, dated Sep. 23, 2019.
Office Action for European App. No. 17203968.7, dated Nov. 14, 2019.
Office Action in Japanese Application No. 2016-553344, dated Apr. 24, 2018.
PCT/US2016/030304_IPRP.
PCT/US2016/030319_IPRP.
Search Report for Brazilian App. No. BR112016019111, dated Mar. 12, 2020.
Search Report for EP App. No. 17203984.4, dated Mar. 29, 2018.
Search Report for European App. No. 19187736.4, dated Dec. 16, 2019.
Search Report in EP App. No. 15752771, dated Nov. 22, 2017.
Related Publications (1)
Number Date Country
20210178365 A1 Jun 2021 US
Provisional Applications (1)
Number Date Country
62519933 Jun 2017 US
Continuations (1)
Number Date Country
Parent 15958337 Apr 2018 US
Child 17185604 US